Buying Models
Please note: Due to strict biomaterials regulations in China, we are unable to ship mouse models, cell lines, or other genetic materials outside national borders.
However, this doesn’t have to be a barrier to collaboration. LIDE routinely partners with universities, biotechs, and global pharma by conducting studies directly in our accredited China facilities. Our team delivers results digitally, and our in-house bioanalytics group ensures raw data is processed, interpreted, and presented in formats ready for regulatory or internal decision-making.
If appropriate, we would be happy to collaborate and provide a tailored study proposal. As a full-service preclinical CRO, we offer both in vitro and in vivo capabilities across oncology and immuno-oncology, supported by one of the largest PDX biobanks worldwide. A summary of our platform features below:
2300 PDX Models
Many with rare mutations or high-profile target expressions. Patient, SOC and genetic data accessible online.
120 CDX Models
Established and ready for cost-effective in-vivo testing.
MiniPDX and IOFIVE
A 7-14 day in-vivo drug screening assay. Cheaper than PDX and still 92% correlated.
Orthotopic Models
Established on PDX, CDX, and hematological tumors, across a wide spectrum of solid and liquid cancers.
Syngeneic Models
Diverse collection of murine tumor cell lines covering solid, blood, and orthotopic model, with or without bioluminescent variants.
Humanized Models
Reconstituted or co-inoculated models provide flexible, high-fidelity solutions for IO drug development.
Ex Vivo Models
Designed for speed, scalability, and biological fidelity, our CR cells and 3D organoids enable better translatability than regular 2D cultures.
Daily Fresh Patient Samples
Received through our 100+ hospital translational network. Tissues can be used in MiniPDX biomarker studies or for IO drug validation.
In-House Multi-Omics
Classical DNA/RNA analysis, next gen proteomics and proprietary multi-level gene signature scoring.